Nestlé parts with peanut al­ler­gy treat­ment Pal­forzia

Peanut al­ler­gies proved a tough nut to crack for Nestlé, which an­nounced Mon­day it has di­vest­ed its treat­ment Pal­forzia to Swiss al­ler­gy spe­cial­ist Stal­ler­genes Greer.

Nestlé ac­quired Pal­forzia in its $2.6 bil­lion takeover of Aim­mune in 2020, months af­ter the peanut pow­der pill be­came the first FDA-ap­proved treat­ment for peanut al­ler­gy. The idea is to grad­u­al­ly ex­pose pa­tients to small but in­creas­ing amounts of the al­ler­gen to build re­sis­tance. Nestlé had high hopes for Pal­forzia, but CEO Mark Schnei­der said on an in­vestor call in No­vem­ber that it end­ed up be­ing more of a “niche ther­a­py” than a block­buster.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER